We expect Vertex Pharmaceuticals VRTX to surpass expectations when it reports its fourth-quarter and full-year 2025 results on Feb. 12, after market close. The Zacks Consensus Estimate for the

International Business Machines Corporation’s IBM QRadar Security Information and Event Management (SIEM) and Security Orchestration, Automation and Response (SOAR) platforms have been integrated

Sanofi SNY announced that the FDA has granted Breakthrough Therapy designation to Wayrilz (rilzabrutinib), a novel oral, reversible Bruton’s tyrosine kinase (BTK) inhibitor, for the treatment of

Quest Diagnostics Inc.’s DGX fourth-quarter 2025 adjusted earnings per share (EPS) of $2.42 beat the Zacks Consensus Estimate by 2.85%. The metric also exceeded the year-ago adjusted figure by 8.5%.

Stocks hitting their 52-week high and delivering consistent performance offer attractive opportunities to investors while building a portfolio. This is because stocks near that level are perceived

CNA Financial Corporation CNA reported fourth-quarter 2025 core earnings of $1.16 per share, which missed the Zacks Consensus Estimate by 3.3%. The bottom line decreased 7.2% year over year.The

Salesforce, Inc. CRM shares have plunged 16.8% over the past six months, underperforming the broader Zacks Computer and Technology sector’s gain of 10.8%.

The sharp contrast raises a tough question

Kimco Realty Corporation KIM is slated to report fourth-quarter 2025 results on Feb. 12, before the opening bell. The company’s quarterly results are likely to display year-over-year growth in

Incyte Corporation INCY reported fourth-quarter 2025 adjusted earnings of $1.80 per share, which missed the Zacks Consensus Estimate of $1.94, primarily due to higher operating expenses. The company